ImmuCell Corporation
ICCC
$5.19
$0.122.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 28.94% | 9.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 28.94% | 9.84% | |||
| Cost of Revenue | 1.91% | 4.37% | |||
| Gross Profit | 104.51% | 28.70% | |||
| SG&A Expenses | 1.36% | -13.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.07% | -3.98% | |||
| Operating Income | 278.88% | 58.54% | |||
| Income Before Tax | 174.33% | 54.23% | |||
| Income Tax Expenses | 361.54% | 0.00% | |||
| Earnings from Continuing Operations | 173.34% | 54.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 173.34% | 54.19% | |||
| EBIT | 278.88% | 58.54% | |||
| EBITDA | 1,598.80% | 114.00% | |||
| EPS Basic | 167.05% | 56.20% | |||
| Normalized Basic EPS | 221.08% | 55.81% | |||
| EPS Diluted | 164.00% | 55.00% | |||
| Normalized Diluted EPS | 221.08% | 55.81% | |||
| Average Basic Shares Outstanding | 9.44% | 4.54% | |||
| Average Diluted Shares Outstanding | 9.44% | 4.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||